ATE433327T1 - Chemisch programmierbare immunität - Google Patents
Chemisch programmierbare immunitätInfo
- Publication number
- ATE433327T1 ATE433327T1 AT00990960T AT00990960T ATE433327T1 AT E433327 T1 ATE433327 T1 AT E433327T1 AT 00990960 T AT00990960 T AT 00990960T AT 00990960 T AT00990960 T AT 00990960T AT E433327 T1 ATE433327 T1 AT E433327T1
- Authority
- AT
- Austria
- Prior art keywords
- molecule
- binding site
- immunity
- human
- sites
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6025—Nucleotides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
- Residential Or Office Buildings (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17170799P | 1999-12-22 | 1999-12-22 | |
PCT/US2000/035179 WO2001045734A1 (en) | 1999-12-22 | 2000-12-21 | Chemically-programmable immunity |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE433327T1 true ATE433327T1 (de) | 2009-06-15 |
Family
ID=22624828
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00990960T ATE433327T1 (de) | 1999-12-22 | 2000-12-21 | Chemisch programmierbare immunität |
Country Status (9)
Country | Link |
---|---|
US (5) | US20030017165A1 (de) |
EP (1) | EP1242115B1 (de) |
AT (1) | ATE433327T1 (de) |
AU (1) | AU3076601A (de) |
CA (1) | CA2328356A1 (de) |
DE (1) | DE60042369D1 (de) |
DK (1) | DK1242115T3 (de) |
ES (1) | ES2328102T3 (de) |
WO (1) | WO2001045734A1 (de) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2328356A1 (en) | 1999-12-22 | 2001-06-22 | Itty Atcravi | Recreational vehicles |
US7645743B2 (en) * | 1999-12-22 | 2010-01-12 | Altermune, Llc | Chemically programmable immunity |
EP2230249A3 (de) | 2003-02-06 | 2010-12-22 | ChronTech Pharma AB | Antigen/Antikörper oder Ligand/Rezeptor glycosylierter Spezifität Austauscher |
US7440877B2 (en) * | 2004-03-12 | 2008-10-21 | General Motors Corporation | System and method for morphable model design space definition |
WO2007056870A1 (en) * | 2005-11-21 | 2007-05-24 | The Governors Of The University Of Alberta | Methods and compositions for pharmacologically controlled targeted immunotherapy |
EP1790358A1 (de) | 2005-11-23 | 2007-05-30 | Université de Reims Champagne-Ardennes | Proteinkonstrukte designed zum Targeting und Lyse von Zellen |
US20100166695A1 (en) * | 2007-03-23 | 2010-07-01 | The Governors Of The University Of Alberta | Multivalent Heterobifunctional Polymers And Methods Of Their Use |
CA2760774A1 (en) | 2009-05-05 | 2010-11-11 | Altermune Technologies, Llc | Chemically programmable immunity |
MA45328A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
MA45469A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Acides nucléiques de bêta-caténine et leurs utilisations |
MA45471A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Acides nucléiques de phosphatidylinositol-3-kinase et leurs utilisations |
MA45468A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Acides nucléiques myc et utilisations |
MA45349A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Acides nucléiques egfr et leurs utilisations |
MA45470A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Acides nucléiques kras et leurs utilisations |
JP2020505330A (ja) | 2017-01-06 | 2020-02-20 | アビディティー バイオサイエンシーズ エルエルシー | エクソンスキッピングを誘導する核酸ポリペプチド組成物および方法 |
GB201711809D0 (en) | 2017-07-21 | 2017-09-06 | Governors Of The Univ Of Alberta | Antisense oligonucleotide |
MX2020003596A (es) | 2017-10-04 | 2020-07-22 | Avidity Biosciences Inc | Composiciones de acido nucleico-polipeptido y usos de las mismos. |
AU2018378812A1 (en) | 2017-12-06 | 2020-07-09 | Avidity Biosciences, Inc. | Compositions and methods of treating muscle atrophy and myotonic dystrophy |
SG11202106593UA (en) | 2018-12-21 | 2021-07-29 | Avidity Biosciences Inc | Anti-transferrin receptor antibodies and uses thereof |
GB201904534D0 (en) | 2019-04-01 | 2019-05-15 | Centauri Therapeutics Ltd | Novel compounds an therapeutic uses thereof |
WO2020247782A1 (en) | 2019-06-06 | 2020-12-10 | Avidity Biosciences, Inc. | Nucleic acid-polypeptide compositions and uses thereof |
IL296387B1 (en) | 2020-03-19 | 2024-04-01 | Avidity Biosciences Inc | Preparations and methods for the treatment of facial, back and arm muscle atrophy |
WO2021195469A1 (en) | 2020-03-27 | 2021-09-30 | Avidity Biosciences, Inc. | Compositions and methods of treating muscle dystrophy |
KR20240055874A (ko) | 2021-09-16 | 2024-04-29 | 어비디티 바이오사이언시스 인크. | 안면견갑상완 근이영양증을 치료하는 조성물 및 방법 |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4169137A (en) * | 1974-12-20 | 1979-09-25 | Block Engineering, Inc. | Antigen detecting reagents |
IL51667A (en) * | 1977-03-16 | 1979-10-31 | Miles Yeda Ltd | Immunoassay for the determination of a hapten |
US5017558A (en) * | 1980-01-14 | 1991-05-21 | The Regents Of The University Of California | Synthetic vaccine peptide epitomes of hepatitis B surface antigen |
US4711955A (en) * | 1981-04-17 | 1987-12-08 | Yale University | Modified nucleotides and methods of preparing and using same |
US4737453A (en) * | 1984-12-12 | 1988-04-12 | Immunomedics, Inc. | Sandwich immunoassay utilizing a separation specific binding substance |
US4637459A (en) * | 1985-06-28 | 1987-01-20 | Roussel Louis J | Anti rotational device for down hole hydraulic pumping unit |
US4940670A (en) * | 1986-01-24 | 1990-07-10 | Rhodes Buck A | Method for compounding and testing patient specific monoclonal antibodies and monoclonal antibody fragments for in vivo use |
SE452065B (sv) * | 1986-04-11 | 1987-11-09 | Ulf R Nilsson | Antikroppspreparation vars antikroppar er specifika for determinanter i c3 b regionen hos denaturerat humant c3 samt dess anvendning och framstellning |
DK8189A (da) * | 1988-01-12 | 1989-07-13 | Bunge Australia | Antigen-antistof-konjugater, deres fremstilling og anvendelse |
US5378815A (en) * | 1989-10-20 | 1995-01-03 | National Research Council Canada | Process for indirect targeted immunocytolysis |
GB8924438D0 (en) | 1989-10-31 | 1989-12-20 | Hoffmann La Roche | Vaccine composition |
US5218088A (en) | 1989-11-02 | 1993-06-08 | Purdue Research Foundation | Process for preparing dithiophosphate oligonucleotide analogs via nucleoside thiophosphoramidite intermediates |
US5683867A (en) * | 1990-06-11 | 1997-11-04 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: blended SELEX |
US6331394B1 (en) | 1991-06-10 | 2001-12-18 | Gilead Sciences, Inc. | Nucleic acid ligands to integrins |
US6261774B1 (en) | 1990-06-11 | 2001-07-17 | Gilead Sciences, Inc. | Truncation selex method |
US6344321B1 (en) | 1990-06-11 | 2002-02-05 | Gilead Sciences, Inc. | Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met |
US5637459A (en) | 1990-06-11 | 1997-06-10 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: chimeric selex |
US5496938A (en) | 1990-06-11 | 1996-03-05 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands to HIV-RT and HIV-1 rev |
JP2763958B2 (ja) * | 1990-06-11 | 1998-06-11 | ネクスター ファーマスーティカルズ,インコーポレイテッド | 核酸リガンド |
US5962219A (en) | 1990-06-11 | 1999-10-05 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: chemi-selex |
US6346611B1 (en) | 1990-06-11 | 2002-02-12 | Gilead Sciences, Inc. | High affinity TGfβ nucleic acid ligands and inhibitors |
US6395888B1 (en) | 1996-02-01 | 2002-05-28 | Gilead Sciences, Inc. | High affinity nucleic acid ligands of complement system proteins |
US6280932B1 (en) | 1990-06-11 | 2001-08-28 | Gilead Sciences, Inc. | High affinity nucleic acid ligands to lectins |
US6232071B1 (en) | 1990-06-11 | 2001-05-15 | Gilead Sciences, Inc. | Tenascin-C nucleic acid ligands |
US6248332B1 (en) * | 1990-10-05 | 2001-06-19 | Medarex, Inc. | Targeted immunostimulation with bispecific reagents |
AU9053991A (en) | 1990-11-20 | 1992-06-11 | Tanox Biosystems, Inc. | Conjugates of anti-idiotype antibodies and carriers and their use in epitope-directed immunization |
WO1995005454A1 (en) | 1992-02-22 | 1995-02-23 | Cambridge Bacteriophage Technologies Ltd. | Engineered bacteriophages and vaccines containing them |
US6579696B1 (en) * | 1992-12-21 | 2003-06-17 | Promega Corporation | Polymyxin B conjugates |
US6040137A (en) * | 1995-04-27 | 2000-03-21 | Tripep Ab | Antigen/antibody specification exchanger |
US6933366B2 (en) * | 1996-12-27 | 2005-08-23 | Tripep Ab | Specificity exchangers that redirect antibodies to bacterial adhesion receptors |
SE9401460D0 (sv) * | 1994-04-28 | 1994-04-28 | Ferring Ab | Antigen/antibody specificity exhanger |
US6660842B1 (en) * | 1994-04-28 | 2003-12-09 | Tripep Ab | Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen |
US6013443A (en) | 1995-05-03 | 2000-01-11 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue SELEX |
EP0833666B1 (de) * | 1996-04-10 | 2003-12-10 | Sangstat Medical Corporation | Zellmodulierende konjugate aus elementen aus spezifischen bindungspaaren |
JP2001512438A (ja) | 1997-02-11 | 2001-08-21 | イムノメディクス,インコーポレイテッド | αガラクトシルエピトープで標識された抗体による免疫応答の刺激 |
US6140091A (en) * | 1997-06-20 | 2000-10-31 | Boston Biomedical Research Institute | Anti-idiotype vaccines to elicit catalytic antibodies |
US6054312A (en) | 1997-08-29 | 2000-04-25 | Selective Genetics, Inc. | Receptor-mediated gene delivery using bacteriophage vectors |
US7112328B2 (en) * | 1998-07-16 | 2006-09-26 | Vincent Marinkovich | Composition for targeted cell treatment |
US6423493B1 (en) | 1998-10-26 | 2002-07-23 | Board Of Regents The University Of Texas System | Combinatorial selection of oligonucleotide aptamers |
WO2001032207A1 (en) * | 1998-10-30 | 2001-05-10 | United States Army Medical Research And Materiel Command | Methods for conferring active/passive immunotherapy |
US6329145B1 (en) | 1999-02-09 | 2001-12-11 | Gilead Science, Inc. | Determining non-nucleic acid molecule binding to target by competition with nucleic acid ligand |
US6280943B1 (en) | 1999-06-17 | 2001-08-28 | Gilead Sciences, Inc. | 2′-fluoropyrimidine anti-calf intestinal phosphatase nucleic acid ligands |
US6387620B1 (en) | 1999-07-28 | 2002-05-14 | Gilead Sciences, Inc. | Transcription-free selex |
EP1088889A1 (de) | 1999-10-01 | 2001-04-04 | University Of Cambridge | Rekombinanter doppelt-hybrider filamentöser Bakteriophage |
EP1223958A4 (de) | 1999-10-27 | 2004-07-21 | Cel Sci Corp | Präparationsmethoden und verbindungen von peptidkonstruktionen die sich zur behandlung von autoimmun- bzw. transplantationsbedingten "host versus graft" pathogenesen eignen |
CA2328356A1 (en) | 1999-12-22 | 2001-06-22 | Itty Atcravi | Recreational vehicles |
US7645743B2 (en) | 1999-12-22 | 2010-01-12 | Altermune, Llc | Chemically programmable immunity |
AU5697001A (en) * | 2000-03-31 | 2001-10-15 | Purdue Research Foundation | Method of treatment using ligand-immunogen conjugates |
US20030017134A1 (en) * | 2001-06-19 | 2003-01-23 | Technion Research And Development Foundation Ltd. | Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer |
US10100316B2 (en) | 2002-11-21 | 2018-10-16 | Archemix Llc | Aptamers comprising CPG motifs |
-
2000
- 2000-12-14 CA CA002328356A patent/CA2328356A1/en not_active Abandoned
- 2000-12-21 WO PCT/US2000/035179 patent/WO2001045734A1/en active Application Filing
- 2000-12-21 DE DE60042369T patent/DE60042369D1/de not_active Expired - Lifetime
- 2000-12-21 AT AT00990960T patent/ATE433327T1/de not_active IP Right Cessation
- 2000-12-21 AU AU30766/01A patent/AU3076601A/en not_active Abandoned
- 2000-12-21 EP EP00990960A patent/EP1242115B1/de not_active Expired - Lifetime
- 2000-12-21 DK DK00990960T patent/DK1242115T3/da active
- 2000-12-21 ES ES00990960T patent/ES2328102T3/es not_active Expired - Lifetime
-
2002
- 2002-06-21 US US10/178,046 patent/US20030017165A1/en not_active Abandoned
-
2003
- 2003-10-29 US US10/696,770 patent/US7422746B2/en not_active Expired - Lifetime
-
2006
- 2006-11-30 US US11/606,564 patent/US7850975B2/en not_active Expired - Fee Related
-
2008
- 2008-12-17 US US12/336,746 patent/US8236321B2/en not_active Expired - Lifetime
-
2012
- 2012-07-06 US US13/543,718 patent/US8591910B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US7850975B2 (en) | 2010-12-14 |
WO2001045734A1 (en) | 2001-06-28 |
EP1242115B1 (de) | 2009-06-10 |
US20070148183A1 (en) | 2007-06-28 |
US20040146515A1 (en) | 2004-07-29 |
EP1242115A4 (de) | 2004-06-16 |
DK1242115T3 (da) | 2009-10-05 |
ES2328102T3 (es) | 2009-11-10 |
EP1242115A1 (de) | 2002-09-25 |
US20120276136A1 (en) | 2012-11-01 |
CA2328356A1 (en) | 2001-06-22 |
US20030017165A1 (en) | 2003-01-23 |
US8236321B2 (en) | 2012-08-07 |
AU3076601A (en) | 2001-07-03 |
US8591910B2 (en) | 2013-11-26 |
US7422746B2 (en) | 2008-09-09 |
DE60042369D1 (de) | 2009-07-23 |
US20090142368A1 (en) | 2009-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE433327T1 (de) | Chemisch programmierbare immunität | |
ATE296105T1 (de) | Iminbildende polysaccharide, deren herstellung und verwendung als zusatzmittel und immunstimulierende mittel | |
DE60130256D1 (de) | Naphthalinderivate, die sich an den ep4?rezeptor binden | |
CY1107628T1 (el) | Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων | |
CA2413190A1 (en) | Methods for treating rheumatic diseases using a soluble ctla4 molecule | |
WO2004010957A3 (en) | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease | |
CY2012003I1 (el) | Αντισωματα που συνδεονται ανοσοειδικως προς blys | |
DK1200418T3 (da) | Nematodicide trifluorbutener | |
BG64475B1 (bg) | Ципразидонови соли | |
AU9399501A (en) | Therapeutic antibodies | |
AU2002364954A1 (en) | ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS | |
BRPI0113286B8 (pt) | pirazóis substituídos e composição farmacêutica compreendendo os mesmos. | |
ATE505208T1 (de) | Rezeptorbindende konjugate | |
ATE198834T1 (de) | Konjugate bestehend aus polysaccharid und protein | |
AR035977A1 (es) | Inmunoconjugados de anticuerpos cd44 citotoxicos. | |
ATE355288T1 (de) | Verbindungen und therapeutische methoden | |
DE69826684D1 (de) | Kovalent gebundenes n,o-carboxymethylchitosan und seine verwendungen | |
DK1327146T3 (da) | Forbindelse med et forgrenet linkermolekyle | |
DE69921486D1 (de) | Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren | |
GB9921592D0 (en) | Preparation of highly pure toxin fragments | |
ITVA20020023A1 (it) | Prodotti per l'edilizia a base di idrossialchilguaro purificato | |
ATE232081T1 (de) | Orale zusammensetzung enthaltend perlit | |
NO20021573L (no) | Tverrbundne kopolymerer basert på ikke-tverrbundne polykarboksyl-kopolymerer | |
EA200000531A1 (ru) | Применение кетолидов для профилактики тромботических артериальных осложнений, связанных с атеросклерозом | |
WO2005048822A3 (en) | Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1242115 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |